{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T07:06:51Z","timestamp":1794640011506,"version":"4.9.1"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat. Biomed. Eng"],"DOI":"10.1038\/s41551-025-01569-4","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T10:02:55Z","timestamp":1765360975000},"page":"732-752","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["A trispecific antibody engaging T cells with tumour and myeloid cells augments antitumour immunity"],"prefix":"10.1038","volume":"10","author":[{"given":"Changrui","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanni","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiyan","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizong","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingzhong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6873-5279","authenticated-orcid":false,"given":"Yucheng T.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bowen","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyi","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Chun","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Libing","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4531-3970","authenticated-orcid":false,"given":"Xing-Ming","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6876-7426","authenticated-orcid":false,"given":"Jieyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8912-5069","authenticated-orcid":false,"given":"Jiwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4007-3856","authenticated-orcid":false,"given":"Wen","family":"Di","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8141-5096","authenticated-orcid":false,"given":"Guanglei","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3106-7593","authenticated-orcid":false,"given":"Fan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"key":"1569_CR1","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.cell.2022.01.008","volume":"185","author":"G Morad","year":"2022","unstructured":"Morad, G. et al. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell 185, 576 (2022).","journal-title":"Cell"},{"key":"1569_CR2","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359, 1350\u20131355 (2018).","journal-title":"Science"},{"key":"1569_CR3","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","volume":"186","author":"P Sharma","year":"2023","unstructured":"Sharma, P. et al. Immune checkpoint therapy-current perspectives and future directions. Cell 186, 1652\u20131669 (2023).","journal-title":"Cell"},{"key":"1569_CR4","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","volume":"377","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan, M., Hopkins, A. & Jaffee, E. M. Tumor mutational burden and response rate to PD-1 inhibition. N. Engl. J. Med. 377, 2500\u20132501 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1569_CR5","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.aaf1490","volume":"351","author":"N McGranahan","year":"2016","unstructured":"McGranahan, N. et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351, 1463\u20131469 (2016).","journal-title":"Science"},{"key":"1569_CR6","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/nrc1586","volume":"5","author":"W Zou","year":"2005","unstructured":"Zou, W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 5, 263\u2013274 (2005).","journal-title":"Nat. Rev. Cancer"},{"key":"1569_CR7","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568\u2013571 (2014).","journal-title":"Nature"},{"key":"1569_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01062-w","volume":"8","author":"M Sade-Feldman","year":"2017","unstructured":"Sade-Feldman, M. et al. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat. Commun. 8, 1136 (2017).","journal-title":"Nat. Commun."},{"key":"1569_CR9","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s43018-022-00335-8","volume":"3","author":"SL Meier","year":"2022","unstructured":"Meier, S. L., Satpathy, A. T. & Wells, D. K. Bystander T cells in cancer immunology and therapy. Nat. Cancer 3, 143\u2013155 (2022).","journal-title":"Nat. Cancer"},{"key":"1569_CR10","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/s41586-018-0130-2","volume":"557","author":"Y Simoni","year":"2018","unstructured":"Simoni, Y. et al. Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature 557, 575\u2013579 (2018).","journal-title":"Nature"},{"key":"1569_CR11","doi-asserted-by":"publisher","first-page":"100856","DOI":"10.1016\/j.xcrm.2022.100856","volume":"3","author":"B Yang","year":"2022","unstructured":"Yang, B. et al. Spatial heterogeneity of infiltrating T cells in high-grade serous ovarian cancer revealed by multi-omics analysis. Cell Rep. Med. 3, 100856 (2022).","journal-title":"Cell Rep. Med."},{"key":"1569_CR12","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41591-018-0266-5","volume":"25","author":"W Scheper","year":"2019","unstructured":"Scheper, W. et al. Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers. Nat. Med. 25, 89\u201394 (2019).","journal-title":"Nat. Med."},{"key":"1569_CR13","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/S0140-6736(23)00521-4","volume":"402","author":"NWCJ van de Donk","year":"2023","unstructured":"van de Donk, N. W. C. J. & Zweegman, S. T-cell-engaging bispecific antibodies in cancer. Lancet 402, 142\u2013158 (2023).","journal-title":"Lancet"},{"key":"1569_CR14","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","volume":"18","author":"AF Labrijn","year":"2019","unstructured":"Labrijn, A. F. et al. Bispecific antibodies: a mechanistic review of the pipeline. Nat. Rev. Drug Discov. 18, 585\u2013608 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1569_CR15","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","volume":"16","author":"MS Topp","year":"2015","unstructured":"Topp, M. S. et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 16, 57\u201366 (2015).","journal-title":"Lancet Oncol."},{"key":"1569_CR16","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau, P. et al. Teclistamab in relapsed or refractory multiple myeloma. N. Engl. J. Med. 387, 495\u2013505 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1569_CR17","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.ccell.2014.09.006","volume":"26","author":"B Ruffell","year":"2014","unstructured":"Ruffell, B. et al. Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell 26, 623\u2013637 (2014).","journal-title":"Cancer Cell"},{"key":"1569_CR18","doi-asserted-by":"publisher","first-page":"5706","DOI":"10.1158\/0008-5472.CAN-21-0536","volume":"81","author":"LSM Lecker","year":"2021","unstructured":"Lecker, L. S. M. et al. TGFBI production by macrophages contributes to an immunosuppressive microenvironment in ovarian cancer. Cancer Res. 81, 5706\u20135719 (2021).","journal-title":"Cancer Res."},{"key":"1569_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110914","volume":"39","author":"D Thumkeo","year":"2022","unstructured":"Thumkeo, D., et al. PGE(2)-EP2\/EP4 signaling elicits immunosuppression by driving the mregDC-Treg axis in inflammatory tumor microenvironment. Cell Rep. 39, 110914 (2022).","journal-title":"Cell Rep."},{"key":"1569_CR20","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41577-019-0127-6","volume":"19","author":"DG DeNardo","year":"2019","unstructured":"DeNardo, D. G. & Ruffell, B. Macrophages as regulators of tumour immunity and immunotherapy. Nat. Rev. Immunol. 19, 369\u2013382 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"1569_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23832-3","volume":"12","author":"F Yang","year":"2021","unstructured":"Yang, F. et al. Synergistic immunotherapy of glioblastoma by dual targeting of IL-6 and CD40. Nat. Commun. 12, 3424 (2021).","journal-title":"Nat. Commun."},{"key":"1569_CR22","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/s41577-023-00867-9","volume":"23","author":"K Chamoto","year":"2023","unstructured":"Chamoto, K. et al. Insights from a 30-year journey: function, regulation and therapeutic modulation of PD1. Nat. Rev. Immunol. 23, 682\u2013695 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"1569_CR23","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","volume":"19","author":"A Chow","year":"2022","unstructured":"Chow, A. et al. Clinical implications of T cell exhaustion for cancer immunotherapy. Nat. Rev. Clin. Oncol. 19, 775\u2013790 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1569_CR24","doi-asserted-by":"publisher","first-page":"328rv4","DOI":"10.1126\/scitranslmed.aad7118","volume":"8","author":"W Zou","year":"2016","unstructured":"Zou, W., Wolchok, J. D. & Chen, L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci. Transl. Med. 8, 328rv4 (2016).","journal-title":"Sci. Transl. Med."},{"key":"1569_CR25","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1172\/JCI96061","volume":"128","author":"H Tang","year":"2018","unstructured":"Tang, H. et al. PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression. J. Clin. Invest. 128, 580\u2013588 (2018).","journal-title":"J. Clin. Invest."},{"key":"1569_CR26","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1158\/0008-5472.CAN-18-3208","volume":"79","author":"H Xiong","year":"2019","unstructured":"Xiong, H. et al. Anti-PD-L1 treatment results in functional remodeling of the macrophage compartment. Cancer Res. 79, 1493\u20131506 (2019).","journal-title":"Cancer Res."},{"key":"1569_CR27","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/s41577-018-0029-z","volume":"18","author":"LB Ivashkiv","year":"2018","unstructured":"Ivashkiv, L. B. IFN\u03b3: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy. Nat. Rev. Immunol. 18, 545\u2013558 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"1569_CR28","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.immuni.2018.03.014","volume":"48","author":"C Sun","year":"2018","unstructured":"Sun, C., Mezzadra, R. & Schumacher, T. N. Regulation and function of the PD-L1 checkpoint. Immunity 48, 434\u2013452 (2018).","journal-title":"Immunity"},{"key":"1569_CR29","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41586-021-03704-y","volume":"596","author":"G Oliveira","year":"2021","unstructured":"Oliveira, G. et al. Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma. Nature 596, 119\u2013125 (2021).","journal-title":"Nature"},{"key":"1569_CR30","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1182\/blood-2008-12-195792","volume":"114","author":"M Ahmadzadeh","year":"2009","unstructured":"Ahmadzadeh, M. et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 114, 1537\u20131544 (2009).","journal-title":"Blood"},{"key":"1569_CR31","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/s41591-019-0522-3","volume":"25","author":"KE Yost","year":"2019","unstructured":"Yost, K. E. et al. Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat. Med. 25, 1251\u20131259 (2019).","journal-title":"Nat. Med."},{"key":"1569_CR32","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.ccell.2022.03.012","volume":"40","author":"KI Hanada","year":"2022","unstructured":"Hanada, K. I. et al. A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers. Cancer Cell 40, 479\u2013493.e6 (2022).","journal-title":"Cancer Cell"},{"key":"1569_CR33","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.immuni.2022.12.002","volume":"56","author":"N Prokhnevska","year":"2023","unstructured":"Prokhnevska, N. et al. CD8+ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effect or differentiation within the tumor. Immunity 56, 107\u2013124.e5 (2023).","journal-title":"Immunity"},{"key":"1569_CR34","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nri2274","volume":"8","author":"RA Seder","year":"2008","unstructured":"Seder, R. A., Darrah, P. A. & Roederer, M. T-cell quality in memory and protection: implications for vaccine design. Nat. Rev. Immunol. 8, 247\u2013258 (2008).","journal-title":"Nat. Rev. Immunol."},{"key":"1569_CR35","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1038\/s41591-021-01398-3","volume":"27","author":"P Voabil","year":"2021","unstructured":"Voabil, P. et al. An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer. Nat. Med. 27, 1250\u20131261 (2021).","journal-title":"Nat. Med."},{"key":"1569_CR36","doi-asserted-by":"publisher","first-page":"3531","DOI":"10.1182\/blood.V93.10.3531.410k32_3531_3539","volume":"93","author":"T Musso","year":"1999","unstructured":"Musso, T. et al. Human monocytes constitutively express membrane-bound, biologically active, and interferon-gamma-upregulated interleukin-15. Blood 93, 3531\u20133539 (1999).","journal-title":"Blood"},{"key":"1569_CR37","doi-asserted-by":"publisher","first-page":"338","DOI":"10.4049\/jimmunol.2100057","volume":"208","author":"TS Kim","year":"2022","unstructured":"Kim, T. S., Rha, M. S. & Shin, E. C. IFN-\u03b3 Induces IL-15 trans-presentation by epithelial cells via IRF1. J. Immunol. 208, 338\u2013346 (2022).","journal-title":"J. Immunol."},{"key":"1569_CR38","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.ccell.2021.04.014","volume":"39","author":"A Bagaev","year":"2021","unstructured":"Bagaev, A. et al. Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer Cell 39, 845\u2013865.e7 (2021).","journal-title":"Cancer Cell"},{"key":"1569_CR39","doi-asserted-by":"publisher","first-page":"5482","DOI":"10.1016\/j.cell.2021.09.014","volume":"184","author":"BA Luca","year":"2021","unstructured":"Luca, B. A. et al. Atlas of clinically distinct cell states and ecosystems across human solid tumors. Cell 184, 5482\u20135496.e28 (2021).","journal-title":"Cell"},{"key":"1569_CR40","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1038\/s43018-024-00828-8","volume":"5","author":"L Lemaitre","year":"2024","unstructured":"Lemaitre, L. et al. Spatial analysis reveals targetable macrophage-mediated mechanisms of immune evasion in hepatocellular carcinoma minimal residual disease. Nat. Cancer 5, 1534\u20131556 (2024).","journal-title":"Nat. Cancer"},{"key":"1569_CR41","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/s41590-020-0620-x","volume":"21","author":"B Diskin","year":"2020","unstructured":"Diskin, B. et al. PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer. Nat. Immunol. 21, 442\u2013454 (2020).","journal-title":"Nat. Immunol."},{"key":"1569_CR42","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/s43018-020-0075-x","volume":"1","author":"SA Oh","year":"2020","unstructured":"Oh, S. A. et al. PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer. Nat. Cancer 1, 681\u2013691 (2020).","journal-title":"Nat. Cancer"},{"key":"1569_CR43","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1038\/s41551-021-00800-2","volume":"5","author":"L Liu","year":"2021","unstructured":"Liu, L. et al. Rejuvenation of tumour-specific T cells through bispecific antibodies targeting PD-L1 on dendritic cells. Nat. Biomed. Eng. 5, 1261\u20131273 (2021).","journal-title":"Nat. Biomed. Eng."},{"key":"1569_CR44","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/nm.3337","volume":"19","author":"SM Pyonteck","year":"2013","unstructured":"Pyonteck, S. M. et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat. Med. 19, 1264\u20131272 (2013).","journal-title":"Nat. Med."},{"key":"1569_CR45","doi-asserted-by":"publisher","first-page":"eabl7882","DOI":"10.1126\/sciadv.abl7882","volume":"8","author":"AR Poh","year":"2022","unstructured":"Poh, A. R. et al. Therapeutic inhibition of the SRC-kinase HCK facilitates T cell tumor infiltration and improves response to immunotherapy. Sci. Adv. 8, eabl7882 (2022).","journal-title":"Sci. Adv."},{"key":"1569_CR46","doi-asserted-by":"publisher","first-page":"eabq3558","DOI":"10.1126\/scitranslmed.abq3558","volume":"15","author":"F Yang","year":"2023","unstructured":"Yang, F. et al. Small-molecule toosendanin reverses macrophage-mediated immunosuppression to overcome glioblastoma resistance to immunotherapy. Sci. Transl. Med. 15, eabq3558 (2023).","journal-title":"Sci. Transl. Med."},{"key":"1569_CR47","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nature19834","volume":"539","author":"MM Kaneda","year":"2016","unstructured":"Kaneda, M. M. et al. PI3K\u03b3 is a molecular switch that controls immune suppression. Nature 539, 437\u2013442 (2016).","journal-title":"Nature"},{"key":"1569_CR48","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003388","volume":"9","author":"K Conlon","year":"2021","unstructured":"Conlon, K. et al. Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors. J. Immunother. Cancer 9, e003388 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"1569_CR49","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1073\/pnas.0307298101","volume":"101","author":"CA Klebanoff","year":"2004","unstructured":"Klebanoff, C. A. et al. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc. Natl Acad. Sci. USA 101, 1969\u20131974 (2004).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1569_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-024-00073-9","volume":"23","author":"A Mullard","year":"2024","unstructured":"Mullard, A. First-in-class IL-15 receptor agonist nabs FDA approval for bladder cancer. Nat. Rev. Drug Discov. 23, 410 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1569_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42155-z","volume":"14","author":"K Wang","year":"2023","unstructured":"Wang, K. et al. Biomimetic nanovaccine-mediated multivalent IL-15 self-transpresentation (MIST) for potent and safe cancer immunotherapy. Nat. Commun. 14, 6748 (2023).","journal-title":"Nat. Commun."},{"key":"1569_CR52","doi-asserted-by":"publisher","first-page":"eabc7804","DOI":"10.1126\/scitranslmed.abc7804","volume":"13","author":"C Hotz","year":"2021","unstructured":"Hotz, C. et al. Local delivery of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models. Sci. Transl. Med. 13, eabc7804 (2021).","journal-title":"Sci. Transl. Med."},{"key":"1569_CR53","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/nri3919","volume":"15","author":"B Jabri","year":"2015","unstructured":"Jabri, B. & Abadie, V. IL-15 functions as a danger signal to regulate tissue-resident T cells and tissue destruction. Nat. Rev. Immunol. 15, 771\u2013783 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"1569_CR54","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/S1074-7613(02)00429-6","volume":"17","author":"S Dubois","year":"2002","unstructured":"Dubois, S. et al. IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells. Immunity 17, 537\u2013547 (2002).","journal-title":"Immunity"},{"key":"1569_CR55","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1084\/jem.20041389","volume":"200","author":"PR Burkett","year":"2004","unstructured":"Burkett, P. R. et al. Coordinate expression and trans presentation of interleukin (IL)-15Ralpha and IL-15 supports natural killer cell and memory CD8+ T cell homeostasis. J. Exp. Med. 200, 825\u2013834 (2004).","journal-title":"J. Exp. Med."},{"key":"1569_CR56","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1182\/blood-2014-01-552174","volume":"123","author":"Y Xu","year":"2014","unstructured":"Xu, Y. et al. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood 123, 3750\u20133759 (2014).","journal-title":"Blood"},{"key":"1569_CR57","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.1158\/0008-5472.CAN-15-1498","volume":"75","author":"K Pilipow","year":"2015","unstructured":"Pilipow, K. et al. IL15 and T-cell stemness in T-cell-based cancer immunotherapy. Cancer Res. 75, 5187\u20135193 (2015).","journal-title":"Cancer Res."},{"key":"1569_CR58","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1158\/2326-6066.CIR-18-0466","volume":"7","author":"D Alizadeh","year":"2019","unstructured":"Alizadeh, D. et al. IL15 enhances CAR-T cell antitumor activity by reducing mTORC1 activity and preserving their stem cell memory phenotype. Cancer Immunol. Res. 7, 759\u2013772 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"1569_CR59","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41587-020-0546-8","volume":"38","author":"MJ Goldman","year":"2020","unstructured":"Goldman, M. J. et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat. Biotechnol. 38, 675\u2013678 (2020).","journal-title":"Nat. Biotechnol."},{"key":"1569_CR60","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan, S. et al. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544\u2013548 (2018).","journal-title":"Nature"},{"key":"1569_CR61","doi-asserted-by":"publisher","first-page":"7470","DOI":"10.1016\/j.cell.2024.10.016","volume":"187","author":"F Lin","year":"2024","unstructured":"Lin, F. et al. Multimodal targeting chimeras enable integrated immunotherapy leveraging tumor-immune microenvironment. Cell 187, 7470\u20137491 e32 (2024).","journal-title":"Cell"},{"key":"1569_CR62","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s43018-023-00536-9","volume":"4","author":"F Cattaruzza","year":"2023","unstructured":"Cattaruzza, F. et al. Precision-activated T-cell engagers targeting HER2 or EGFR and CD3 mitigate on-target, off-tumor toxicity for immunotherapy in solid tumors. Nat. Cancer 4, 485\u2013501 (2023).","journal-title":"Nat. Cancer"}],"container-title":["Nature Biomedical Engineering"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41551-025-01569-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-025-01569-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-025-01569-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T22:02:36Z","timestamp":1776808956000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41551-025-01569-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":62,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["1569"],"URL":"https:\/\/doi.org\/10.1038\/s41551-025-01569-4","relation":{},"ISSN":["2157-846X"],"issn-type":[{"value":"2157-846X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,10]]},"assertion":[{"value":"16 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.L and J.W. are employees of Lyvgen Biopharma. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}